{"id":"NCT00510484","sponsor":"Solvay Pharmaceuticals","briefTitle":"Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","officialTitle":"A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2007-08-02","resultsPosted":"2009-07-20","lastUpdate":"2010-06-03"},"enrollment":35,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Pancrelipase Delayed Release","otherNames":[]},{"type":"DRUG","name":"Placebo Comparator","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.","primaryOutcome":{"measure":"Coefficient of Fat Absorption (%)","timeFrame":"5 days","effectByArm":[{"arm":"Pancrelipase","deltaMin":88.62,"sd":6.62},{"arm":"Placebo","deltaMin":49.78,"sd":18.33}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":23,"countries":["United States","Hungary","Israel","South Africa","Spain"]},"refs":{"pmids":["19815466"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Gastrointestinal and abdominal pain (Excl oral and throat)","Flatulence, Bloating and Distension","Headaches NEC","Faeces abnormal","Physical Examination Procedures"]}}